Deficiency of CCAAT/enhancer binding protein family DNA binding prevents malignant conversion of adenoma to carcinoma in NNK-induced lung carcinogenesis in the mouse

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Kimura, Shioko ^a   Paiz, Jorge ^a   Yoneda, Mitsuhiro ^a   Kido, Taketomo ^a   Vinson, Charles ^a   Ward, Jerrold M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Global VetPathology   (United States)

Author keywords

4 (methylnitrosamino) 1 (3 pyridyl) 1 butanone; A C EBP; C EBPs; Dominant negative; Lung chemical carcinogenesis bioassay; NNK; Transgenic mouse

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CCAAT ENHANCER BINDING PROTEIN; CLARA CELL SECRETORY PROTEIN; DOXYCYCLINE; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA BINDING; LUNG ADENOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ADENOMA; ANIMALS; CARCINOMA; CCAAT-ENHANCER-BINDING PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; IN SITU NICK-END LABELING; INCIDENCE; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; NITROSAMINES; PULMONARY ALVEOLI; TUMOR MARKERS, BIOLOGICAL;

MUS MUSCULUS;

EID: 84870915490     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-90     Document Type: Article

References (35)

1. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 2005, 118:2545-2555. 10.1242/jcs.02459, 15944395.
2. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002, 365:561-575. 1222736, 12006103.
3. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 2007, 17:318-324. 10.1016/j.tcb.2007.07.004, 17658261.
4. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol 2002, 22:6321-6335. 10.1128/MCB.22.18.6321-6335.2002, 135624, 12192032.
5. Newman JR, Keating AE. Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science 2003, 300:2097-2101. 10.1126/science.1084648, 12805554.
6. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res 2005, 11:3184-3190. 10.1158/1078-0432.CCR-04-2625, 15867211.
7. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG. Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 2002, 62:528-534.
8. Loomis KD, Zhu S, Yoon K, Johnson PF, Smart RC. Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis. Cancer Res 2007, 67:6768-6776. 10.1158/0008-5472.CAN-07-0139, 17638888.
9. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270. 10.1038/85820, 11242107.
10. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, Larsen RJ, Asou H, Miller CW, Hoelzer D, Koeffler HP. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002, 99:1332-1340. 10.1182/blood.V99.4.1332, 11830484.
11. Truong BT, Lee YJ, Lodie TA, Park DJ, Perrotti D, Watanabe N, Koeffler HP, Nakajima H, Tenen DG, Kogan SC. CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 2003, 101:1141-1148. 10.1182/blood-2002-05-1374, 12393450.
12. Shim M, Powers KL, Ewing SJ, Zhu S, Smart RC. Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res 2005, 65:861-867.
13. Zahnow CA, Younes P, Laucirica R, Rosen JM. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 1997, 89:1887-1891. 10.1093/jnci/89.24.1887, 9414177.
14. Raught B, Gingras AC, James A, Medina D, Sonenberg N, Rosen JM. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996, 56:4382-4386.
15. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 1991, 5:1538-1552. 10.1101/gad.5.9.1538, 1840554.
16. Berg T, Didon L, Nord M. Ectopic expression of C/EBPalpha in the lung epithelium disrupts late lung development. Am J Physiol Lung Cell Mol Physiol 2006, 291:L683-L693. 10.1152/ajplung.00497.2005, 16698852.
17. Cassel TN, Nord M. C/EBP transcription factors in the lung epithelium. Am J Physiol Lung Cell Mol Physiol 2003, 285:L773-L781.
18. Tomita T, Kido T, Kurotani R, Iemura S, Sterneck E, Natsume T, Vinson C, Kimura S. CAATT/enhancer-binding proteins alpha and delta interact with NKX2-1 to synergistically activate mouse secretoglobin 3A2 gene expression. J Biol Chem 2008, 283:25617-25627. 10.1074/jbc.M805140200, 2533088, 18632661.
19. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 2006, 98:396-406. 10.1093/jnci/djj093, 16537832.
20. Armstrong DA, Phelps LN, Vincenti MP. CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells. Mol Cancer Res 2009, 7:1517-1524. 10.1158/1541-7786.MCR-09-0082, 19723873.
21. Oh WJ, Rishi V, Orosz A, Gerdes MJ, Vinson C. Inhibition of CCAAT/enhancer binding protein family DNA binding in mouse epidermis prevents and regresses papillomas. Cancer Res 2007, 67:1867-1876. 10.1158/0008-5472.CAN-06-2746, 17308129.
22. Kido T, Tomita T, Okamoto M, Cai Y, Matsumoto Y, Vinson C, Maru Y, Kimura S. FOXA1 plays a role in regulating secretoglobin 1a1 expression in the absence of CCAAT/enhancer binding protein activities in lung in vivo. Am J Physiol Lung Cell Mol Physiol 2011, 300:L441-L452. 10.1152/ajplung.00435.2009, 3064285, 21224212.
23. Hecht SS, Morse MA, Amin S, Stoner GD, Jordan KG, Choi CI, Chung FL. Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis 1989, 10:1901-1904. 10.1093/carcin/10.10.1901, 2791206.
24. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011, 278:16-27. 10.1111/j.1742-4658.2010.07919.x, 21087457.
25. Rucci N, Sanita P, Angelucci A. Roles of metalloproteases in metastatic niche. Curr Mol Medicine 2011, 11:609-622.
26. Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res 2011, 71:6010-6018. 10.1158/0008-5472.CAN-11-0595, 3174331, 21803744.
27. Rehm S, Ward JM, ten Have-Opbroek AA, Anderson LM, Singh G, Katyal SL, Rice JM. Mouse papillary lung tumors transplacentally induced by N-nitrosoethylurea: evidence for alveolar type II cell origin by comparative light microscopic, ultrastructural, and immunohistochemical studies. Cancer Res 1988, 48:148-160.
28. Renne R, Brix A, Harkema J, Herbert R, Kittel B, Lewis D, March T, Nagano K, Pino M, Rittinghausen S, Rosenbruch M, Tellier P, Wohrmann T. Proliferative and nonproliferative lesions of the rat and mouse respiratory tract. Toxicol Pathol 2009, 37:5S-73S. 10.1177/0192623309353423, 20032296.
29. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Internatl J Clinic Experi Pathol 2011, 4:444-453.
30. Vincent-Salomon A, Hajage D, Rouquette A, Cedenot A, Gruel N, Alran S, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Kirova Y. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients. Breast 2012, 21:380-383. 10.1016/j.breast.2012.03.005, 22531230.
31. Zhang L, Hu S, Korteweg C, Chen Z, Qiu Y, Su M, Gu J. Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Hum Pathol 2012, 43:423-434. 10.1016/j.humpath.2011.05.020, 21855109.
32. Agrawal S, Hofmann WK, Tidow N, Ehrich M, van den Boom D, Koschmieder S, Berdel WE, Serve H, Muller-Tidow C. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007, 109:3895-3905. 10.1182/blood-2006-08-040147, 17234736.
33. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R, Sterneck E. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J 2010, 29:4106-4117. 10.1038/emboj.2010.280, 3018791, 21076392.
34. Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D'Amato R, Folkman J. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J: official publication of the Federation of American Societies for Experimental Biology 2008, 22:3728-3735.
35. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, Fraire AE, Gabrielson EW, Gunning WT, Haines DC, Kaufman MH, Linnoila RI, Maronpot RR, Rabson AS, Reddick RL, Rehm S, Rozengurt N, Schuller HM, Shmidt EN, Travis WD, Ward JM, Jacks T. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004, 64:2307-2316. 10.1158/0008-5472.CAN-03-3376, 15059877.